The current COVID-19 situation is challenging and difficult for all of us - we hope this virtual conference will allow colleagues to share and discuss their latest research, while under travel and stay-at-home restrictions.
The eleventh meeting on Neurodegenerative Diseases is going fully virtual and will begin late morning EST on Wednesday, December 2, and will conclude late afternoon EST on Friday, December 4, 2020.
A primary goal of the meeting is to provide a forum where biomedical scientists from academia can interact with scientists from the biopharmaceutical industry, thus forging a community of academic and industry researchers who recognize that they have much to learn from each other. Rational drug discovery for neurodegenerative diseases has begun to yield compounds and treatments that are now entering clinical settings. For human studies utilizing these compounds and treatments to be maximally informative, it is crucial that scientists from academia and industry meet regularly to exchange data and ideas.
This meeting will consist of six oral sessions plus a poster session throughout the meeting. Oral sessions will include a combination of invited speakers and talks selected from submitted abstracts.
|Day ||Time (EST) ||Session # ||Session Name |
||10:00 am - 11:00 am
||Keynote Speaker: Virginia Lee |
||11:00 am - 1:00 pm
||Genetics, Genomics and Target Identification in Neurodegenerative Disease |
||2:00 pm - 5:00 pm
||Neuroinflammation and Glial Biology of Neurodegeneration |
||10:00 am- 1:00 pm
||Therapeutic Initiatives in Neurodegenerative Disease |
||2:00 pm - 5:00 pm
||ApoE and Lipid Metabolism |
||10:00 am- 12:45 pm
||Endolysosomal Dysfunction in Neurodegeneration |
||1:30 pm- 3:00 pm
||Panel: Science, Society and COVID-19 |
||3:00 pm - 6:00 pm
||New Technologies to Study Neurodegeneration |
||Virtual Poster Session |
||Wednesday, 5:30 pm
|StemCell Technologies Workshop
||Thursday, 5:30 pm
||Friday, 6:00 pm
Christopher Henderson, Biogen
Joachim Herz, UT Southwestern
Henne Holstege, Vrije Universiteit Amsterdam, Netherlands
Sally John, Biogen
Anne Schaefer, Icahn School of Medicine at Mount Sinai
Robert Brown, University of Massachusetts Medical School
Olav Michael Andersen, Aarhus University, Denmark
Frank Bennett, Ionis Pharmaceuticals
Gonçalo Castelo-Branco, Karolinska Institutet, Sweden
Michael Heneka, German Center for Neurodegenerative Diseases (DZNE)
David Holtzman, Washington University School of Medicine
Yadong Huang, University of California, San Francisco
Martin Kampmann, University of California, San Francisco
Jennifer Lippincott-Schwartz, HHMI Janelia Farm Research Campus
Leonard Petrucelli, Mayo Clinic
Virginia Lee, University of Pennsylvania Perelman School of Medicine
Abstracts should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Selection of material for oral and poster presentations will be made by the organizers and individual session chairs. The status of abstracts (i.e., talk or poster) will be posted as soon as decisions have been made by the organizers. Please bring this announcement to the attention of any of your colleagues who may be interested in participating in the meeting.
All questions pertaining to registration, fees, abstract submission or any other matters may be directed to Catie Carr at email@example.com.
Cold Spring Harbor Laboratory is eager to have as many young people as possible attend this meeting. As such, we have some funds set aside to partially support students and postdocs. Please register and apply in writing to Catie Carr at firstname.lastname@example.org stating your eligibility and need for financial support. Preference will be given to those submitting abstracts.
Partial support for this meeting provided by: National Institute of Neurological Diseases & Stroke
Meeting sponsored by:
The designated hashtag for this meeting is #cshldegen. Note that you must obtain permission from an individual presenter before live-tweeting or discussing his/her talk, poster, or research results on social media. Click the Policies tab above to see our full Confidentiality & Reporting Policy.
Late Pricing: (registrations submitted after 4:01 p.m. EDT on November 25, 2020)
Late Virtual Academic Package: $340
Late Virtual Graduate Student Package: $245
Late Virtual Corporate Package: $460
Virtual Reduced Package (LMIC/MSI only): $25 (see special support from IBRO and CZI below)
IBRO/International Brain Research Organization are generously supporting the participation of a limited number of individuals from US/Canadian Minority Serving Institutions
Limit: 65 attendees / limit per institution: 5
Chan Zuckerberg Initiative are generously supporting the participation of a limited number of individuals from Low & Middle Income Countries or US/Canadian Minority Serving Institutions
Limit: 300 attendees / limit per institution: 10 (including IBRO support)
Reduced Pricing for Individuals from US/Canadian Minority Serving Institutions (check eligibility): $25
Reduced Pricing for Individuals from Low & Middle Income Countries (check eligibility): $25